A new clinical trial published in the ‘Journal of Clinical Oncology’ reported that adavosertib can significantly reduce the tumor regrowth and improve survival rates in metastatic colorectal cancer patients.
In this study, patients with metastatic colorectal cancer who have mutations in TP53 and RAS genes were included. The patients who were stable or responded after 16 weeks of chemotherapy were randomly divided in adavosertib and active monitoring groups.
Adavosertib, 250 or 300 mg was administered once orally on days 1-5 and days 8-12 of a 3-week cycle. Progression free survival was evaluated following drug administration. Patients who were administered with adavosertib showed delayed tumor growth with minimal side effects. Also, the survival rates were increased in patients with left-sided/rectal tumors.
Taken together, adavosertib was well tolerated and effective to treat patients with RAS or TP53 colorectal cancer. These are early results and large trials are needed to establish survival benefits.
Also, learn some natural remedies to prevent risk of colorectal cancer.
|Source||Journal of Clinical Oncology|
|Original title of the article||Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring|